Naveed Ummed, MD
Psychiatry · Johns Creek, GANPI 1841597770
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 26.2% of the total. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$885
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$839
- Otsuka America Pharmaceutical, Inc.$752
- Alkermes, Inc.$730
- Takeda Pharmaceuticals U.S.A., Inc.$500
- plus $2K from 17 others
Across 4 payments — averaging $5891.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$24K
What the payments were for
- Travel & lodging$5897%
- Food & beverage$7,58291%
- Education$1732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 64 | $2,183 |
| AbbVie(2 entities) | 56 | $885 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $839 |
| Otsuka America Pharmaceutical, Inc. | 28 | $752 |
| Alkermes, Inc. | 36 | $730 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $500 |
| Lundbeck LLC | 27 | $435 |
| Sunovion Pharmaceuticals Inc. | 24 | $413 |
| Teva Pharmaceuticals USA, Inc. | 14 | $322 |
| Neurocrine Biosciences, Inc. | 16 | $316 |
| Vanda Pharmaceuticals Inc. | 11 | $227 |
| Supernus Pharmaceuticals, Inc. | 16 | $187 |
| E.r. Squibb & Sons, L.L.C. | 1 | $128 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Boehringer Ingelheim | 1 | $70 |
| Shire North American Group Inc | 5 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $44 |
| Almatica Pharma LLC | 2 | $38 |
| Corium, LLC | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Brainsway USA Inc | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,343 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 52 | $53,333 |
| RexultiBrexpiprazole | 23 | $44,962 |
| Invega SustennaPaliperidone Palmitate | 15 | $32,391 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $27,701 |
| Risperdal ConstaRisperidone Microspheres | 13 | $14,308 |
| Duloxetine Hcl | 83 | $1,751 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $1,169 |
| Clozapine | 18 | $1,047 |
| Gabapentin | 37 | $771 |
| Haloperidol Decanoate | 14 | $716 |
| Bupropion XlBupropion Hcl | 17 | $714 |
| Naltrexone Hcl | 11 | $663 |
| Doxepin Hcl | 21 | $610 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $575 |
| Carbamazepine | 13 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna, Risperdal Consta | $2,183 | $100,03280 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $752 | $44,96223 claims |
| Alkermes, Inc.Lybalvi | $730 | $27,70113 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $11317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Johns Creek
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.